InsidersTradesSigma
Follow the HLB stock price and the full insider trade history of the company, a publicly traded company based in South Korea. Shares are listed on the KR market, under the supervision of DART (FSS). Operating in the Health Care sector, HLB has logged 54 public disclosures. Market capitalisation: €5,620.6bn. The latest transaction was disclosed on 9 June 2026 (Purchase). Among the most active insiders: 진양곤. Every trade is free.
52
Insider Decl.
n/a
Thresholds
n/a
28 ops.
Buy Volume
n/a
2 ops.
Sell Volume
Fundamental score
Ranked 24,906 of 29,055 companies
26.2
score / 100
Value26
Quality27
FCF yld-2.4%
Earn yld-4.8%
EV/EBITDA·
ROE-48%
Gross mgn33%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 9 June 2026
Declarations54 total
Other
Other
1,391,297 sharesKRXDART:20260609000183
44,728 sharesKRXDART:20260303001765
25 of 54 declarations
Acerca de HLB
HLB es una empresa farmacéutica y de atención médica que cotiza en el mercado XKRX. Se enfoca en el desarrollo de tratamientos y soluciones terapéuticas innovadoras.